AstraZeneca is working with DxS to commercialize a EGFR mutation test kit in Europe to identify the patient population most likely to benefit from treatment with non-small cell lung cancer drug Iressa. The company has announced no such plans in the US, where the FDA has restricted any new NSCLC patients from receiving the drug.
New data presented at the International Conference on Alzheimer's Disease by Allen Roses and his team from Duke University may lead to the development of a new diagnostic test that can predict whether a person will develop Alzheimer's and at what age.
Under the partnership announced this week, DxS' RT-PCR technology will be joined with Exosome Dx's xOSO technology — which collects nucleic acids from blood exosomes — to develop blood-based companion diagnostics for detecting cancer gene mutations.
In a paper appearing online today in Nature Methods, University of Cambridge and Applied Biosystems researchers demonstrated that they could use mRNA-sequencing to evaluate the transcriptomes of single mouse cells.